Dynamics of tumor-infiltrating lymphocytes (TILs) during neoadjuvant dual HER2 blockade in HER2-positive (HER2+) breast cancer in the absence of chemotherapy

被引：1
|
作者：
Griguolo, G.
Holgado, E.
Cortes, J.
Fasani, R.
Pascual, T.
Pare, L.
Bermejo, B.
Oliveira, M.
Morales, S.
Martinez, N.
Vidal, M.
Pernas, S.
Lopez, R.
Munoz, M.
Galvan, P.
Garau, I.
Manso, L.
Alarcon, J.
Martinez, E.
Villagrasa, P.
LLombart-Cussac, A.
机构：
[1] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
[2] Univ Padua, Padua, Italy
[3] Hosp Univ Ramon & Cajal, Madrid, Spain
[4] Vall dHebron Inst Oncol, Mol Oncol Grp, Barcelona, Spain
[5] SOLTI Breast Canc Res Grp, Barcelona, Spain
[6] Hosp Clin Univ Valencia, INCLIVA, CIBERONC, Valencia, Spain
[7] Vall dHebron Univ Hosp, Barcelona, Spain
[8] Hosp Univ Arnau de Vilanova Lleida, Lleida, Spain
[9] Inst Catala Oncol, Lhospitalet De Llobregat, Hospitalet Del, Spain
[10] Hosp Clin Univ Santiago, Santiago De Compostela, Spain
[11] Hosp Son Llatzer, Palma De Mallorca, Spain
[12] Hosp Univ 12 Octubre, Madrid, Spain
[13] Hosp Univ Son Espases, Palma De Mallorca, Spain
[14] Consorcio Hosp Prov Castellon, Castellon De La Plana, Spain
[15] Hosp Univ Arnau de Vilanova Valencia, Valencia, Spain
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P6-17-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-17-08
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
    Liefaard, M. C.
    van der Voort, A.
    van Seijen, M.
    Thijssen, B.
    Sanders, J.
    Vonk, S.
    Mittempergher, L.
    Bhaskaran, R.
    de Munck, L.
    van Leeuwen-Stok, A. E.
    Salgado, R.
    Horlings, H. M.
    Lips, E. H.
    Sonke, G. S.
    [J]. NPJ BREAST CANCER, 2024, 10 (01)
  • [2] Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
    Nuciforo, P.
    Prat, A.
    Llombart, A.
    Fasani, R.
    Pare, L.
    Pascual, T.
    Oliveira, M.
    Martinez Janez, N.
    Bermejo De las Heras, B.
    Vidal, M.
    Pernas Simon, S.
    Lopez, R.
    Munoz, M.
    Garau, I.
    Manso, L.
    Alarcon Company, J.
    Martinez de Duenas, E.
    Villagrasa Gonzalez, P.
    Cortes Castan, J.
    Holgado, E.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [3] Tumor-infiltrating lymphocytes and response prediction to neoadjuvant chemotherapy in HER2-positive breast cancer
    Heppner, B. Ingold
    Untch, M.
    Denkert, C.
    Pfitzner, B. M.
    Lederer, B.
    Schmidt, W.
    Eidtmann, H.
    Fasching, P.
    Tesch, H.
    Solbach, C.
    Rezai, M.
    Zahm, D. -M.
    Holms, F.
    Glados, M.
    Krabisch, P.
    Heck, E.
    Ober, A.
    Lorenz, P.
    Diebold, K.
    Habeck, J.
    Loibl, S.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 5 - 5
  • [4] Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
    Advani, Pooja
    Cornell, Lauren
    Chumsri, Saranya
    Moreno-Aspitia, Alvaro
    [J]. BREAST CANCER-TARGETS AND THERAPY, 2015, 7 : 321 - 335
  • [5] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer
    C. Criscitiello
    A. Vingiani
    P. Maisonneuve
    G. Viale
    G. Viale
    G. Curigliano
    [J]. Breast Cancer Research and Treatment, 2020, 183 : 347 - 354
  • [6] Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer
    Sanfeliu, Esther
    Braso-Maristany, Fara
    Dieci, Maria Vittoria
    Marin-Aguilera, Mercedes
    Gonzalez-Farre, Blanca
    Griguolo, Gaia
    Pascual, Tomas
    Galvan, Patricia
    Angelats, Laura
    Castillo, Oleguer
    Blasco, Paula
    Sirenko, Valeria
    Jares, Pedro
    Puig-Butille, Joan Anton
    Pare, Laia
    Martinez, Antonio
    Llombart-Cussac, Antonio
    Cortes, Javier
    Vivancos, Ana
    Villagrasa, Patricia
    Parker, Joel S.
    Perou, Charles M.
    Prat, Aleix
    Conte, PierFranco
    Guarneri, Valentina
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [7] Dual HER2 blockade in adjuvant and neoadjuvant treatment of HER2-positive breast cancer: the role of pertuzumab
    Duchnowska, Renata
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (01): : 43 - 47
  • [8] Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
    Luque, Melani
    Sanz-Alvarez, Marta
    Morales-Gallego, Miriam
    Madoz-Gurpide, Juan
    Zazo, Sandra
    Dominguez, Carolina
    Cazorla, Alicia
    Izarzugaza, Yann
    Arranz, Juan Luis
    Cristobal, Ion
    Rojo, Federico
    [J]. CANCERS, 2022, 14 (24)
  • [9] Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
    Fara Brasó-Maristany
    Gaia Griguolo
    Tomás Pascual
    Laia Paré
    Paolo Nuciforo
    Antonio Llombart-Cussac
    Begoña Bermejo
    Mafalda Oliveira
    Serafín Morales
    Noelia Martínez
    Maria Vidal
    Barbara Adamo
    Olga Martínez
    Sonia Pernas
    Rafael López
    Montserrat Muñoz
    Núria Chic
    Patricia Galván
    Isabel Garau
    Luis Manso
    Jesús Alarcón
    Eduardo Martínez
    Sara Gregorio
    Roger R. Gomis
    Patricia Villagrasa
    Javier Cortés
    Eva Ciruelos
    Aleix Prat
    [J]. Nature Communications, 11
  • [10] Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
    Braso-Maristany, Fara
    Griguolo, Gaia
    Pascual, Tomas
    Pare, Laia
    Nuciforo, Paolo
    Llombart-Cussac, Antonio
    Bermejo, Begona
    Oliveira, Mafalda
    Morales, Serafin
    Martinez, Noelia
    Vidal, Maria
    Adamo, Barbara
    Martinez, Olga
    Pernas, Sonia
    Lopez, Rafael
    Munoz, Montserrat
    Chic, Nuria
    Galvan, Patricia
    Garau, Isabel
    Manso, Luis
    Alarcon, Jesus
    Martinez, Eduardo
    Gregorio, Sara
    Gomis, Roger R.
    Villagrasa, Patricia
    Cortes, Javier
    Ciruelos, Eva
    Prat, Aleix
    [J]. NATURE COMMUNICATIONS, 2020, 11 (01)
12345